Indocyanine Green and Methylene Blue Dye Guided Sentinel Lymph Node Biopsy in Early Breast Cancer: A Single-Center Retrospective Survival Study in 1574 Patients.

[1]  H. Kamma,et al.  Long-term results of fluorescence and indigo carmine blue dye-navigated sentinel lymph node biopsy , 2021, International Journal of Clinical Oncology.

[2]  J. Ou,et al.  Clinical study of combined application of indocyanine green and methylene blue for sentinel lymph node biopsy in breast cancer , 2021, Medicine.

[3]  Houpu Yang,et al.  Long-term follow-up results of fluorescence and blue dye guided sentinel lymph node biopsy in early breast cancer , 2021, Breast Cancer Research and Treatment.

[4]  E. Song,et al.  Current Status and Factors Influencing Surgical Options for Breast Cancer in China: A Nationwide Cross-Sectional Survey of 110 Hospitals. , 2020, The oncologist.

[5]  Huang Li,et al.  Factors that affect the false negative rate of sentinel lymph node mapping with methylene blue dye alone in breast cancer , 2019, The Journal of international medical research.

[6]  F. Cardoso,et al.  Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Qi,et al.  Sentinel lymph node biopsy mapped with methylene blue dye alone in patients with breast cancer: A systematic review and meta-analysis , 2018, PloS one.

[8]  Q. Sun,et al.  Comparison of sentinel lymph node biopsy guided by blue dye with or without indocyanine green in early breast cancer , 2018, Journal of surgical oncology.

[9]  J. Benson,et al.  Axillary surgery in breast cancer: the beginning of the end. , 2018, Minerva chirurgica.

[10]  P. Liu,et al.  Comparison of sentinel lymph node biopsy guided by indocyanine green, blue dye, and their combination in breast cancer patients: a prospective cohort study , 2017, World Journal of Surgical Oncology.

[11]  Ping Chen,et al.  Indocyanine green detects sentinel lymph nodes in early breast cancer , 2017, The Journal of international medical research.

[12]  J. de Boniface,et al.  Ten‐year report on axillary recurrence after negative sentinel node biopsy for breast cancer from the Swedish Multicentre Cohort Study , 2017, The British journal of surgery.

[13]  M. Toi,et al.  Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis , 2017, International Journal of Clinical Oncology.

[14]  Q. Sun,et al.  Diagnostic Performance of Indocyanine Green-Guided Sentinel Lymph Node Biopsy in Breast Cancer: A Meta-Analysis , 2016, PloS one.

[15]  H. Inaji,et al.  Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer , 2016, Breast Cancer.

[16]  A. Luini,et al.  Long-term follow-up of 5262 breast cancer patients with negative sentinel node and no axillary dissection confirms low rate of axillary disease. , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  A. Purushotham,et al.  Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review. , 2014, The Lancet. Oncology.

[18]  Y. Ogawa,et al.  Outcome of sentinel lymph node biopsy in breast cancer using dye alone: a single center review with a median follow-up of 5 years , 2014, Surgery Today.

[19]  Masakazu Toi,et al.  Comparison of the Indocyanine Green Fluorescence and Blue Dye Methods in Detection of Sentinel Lymph Nodes in Early-stage Breast Cancer , 2013, Annals of Surgical Oncology.

[20]  Petri Välisuo,et al.  A Review of Indocyanine Green Fluorescent Imaging in Surgery , 2012, Int. J. Biomed. Imaging.

[21]  Kei Aoyama,et al.  Sentinel lymph node biopsy for breast cancer patients using fluorescence navigation with indocyanine green , 2011, World journal of surgical oncology.

[22]  T. Julian,et al.  Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. , 2010, The Lancet. Oncology.

[23]  Michael Hünerbein,et al.  ICG fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer , 2010, Breast Cancer Research and Treatment.

[24]  V. Speirs,et al.  Properties and characteristics of the dyes injected to assist axillary sentinel node localization in breast surgery. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[25]  Gary H Lyman,et al.  Lymphatic mapping and sentinel lymph node biopsy in early‐stage breast carcinoma , 2006, Cancer.

[26]  M. Kokke,et al.  Incidence of axillary recurrence in 113 sentinel node negative breast cancer patients: a 3-year follow-up study. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[27]  A. Luini,et al.  Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. , 2005, European journal of cancer.